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Ethnopharmacological Relevance. Natural products, like Flaxseed (Linum usitatissimum), have traditionally been used in
inflammatory bowel disease (IBD). It is known to contain multiple constituents which may account for its effectiveness, as
IBD is a multifaceted disease. Aim of the Study. In the current study, we aimed to assess pharmacological basis for the
medicinal use of Flaxseed in IBD. Materials and Methods. Aqueous-methanolic crude extracts of Flaxseed (Fs.Cr) and
Flaxseed oil were tested against 6% acetic acid- (AA-) induced colitis in BALB/c mice. Microscopic damage parameters of the
hematoxylin and eosin-stained and periodic acid-Schiff-alcian blue-stained sections of the colon were scored to be assessed.
Possible antispasmodic mechanism was studied on isolated rabbit jejunum, while antibacterial activity was assessed in vitro
for microbes implicated in IBD. Results. In AA-induced colitis, Flaxseed oil was found to be more effective in reducing
mortality and colonic ulcers than Fs.Cr at 500mg/kg dose. Fs.Cr was more efficacious in increasing mucin content as
compared to oil, exhibiting slightly greater anti-inflammatory effect (50% vs 35%) and reducing depth of lesion (55% vs
42.31%, respectively). Antispasmodic activity of Fs.Cr (0.03 and 0.1mg/ml) was mediated by phosphodiesterase inhibitors
(PDEI, possibly PDE-4 subtype) with a resultant increase in cAMP levels. Flaxseed oil PDEI activity was mild (1 and 3mg/
ml). Fs.Cr (0.1 and 0.3 mg/ml) was potent in exhibiting anticholinergic activity, similar to dicyclomine, whereas Flaxseed oil
showed anticholinergic effect at 1 and 3mg/ml. Flaxseed oil (9 and 14 µg/ml) was bactericidal against enteropathogenic E.coli
(EPEC), enterotoxigenic E.coli (ETEC), and enteroaggregative E.coli (EAEC), whereas Fs.Cr exhibited bactericidal effect
against EPEC at 100 µg/ml. Conclusions. Results of this study, taken together with previous studies, suggest that Flaxseed
possesses anti-inflammatory, antibacterial, and antispasmodic action through multiple pathways and thus offers promising
potential to be developed for IBD.
1. Introduction
Inflammatory bowel disease (IBD) is a heterogeneous dis-
ease in which multiple triggers act simultaneously. (e
major maneuvering targets in IBD are immune dysregula-
tion, barrier, and microbial defects, along with abdominal
spasms and colic as accompanying symptoms [1]. Despite
advancement in IBD therapeutics, rate of failure to attain the
remission remains high possibly due to multifactorial eti-
ology of the disease.
Flaxseed (scientific name: Linum usitatissimum) has
traditionally been used for IBD [2, 3]. In our earlier studies,
we provided some evidence for its traditional use by showing
that the aqueous-methanolic crude extract of Flaxseed
(Fs.Cr) ameliorated the severity in mice model of colitis by
reducing mediators of inflammation (myeloperoxidase and
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cytokines) and inducers of oxidative stress [4]. (e extract
that we studied comprised predominantly of polar com-
ponents, whereas Flaxseed as a whole is a combination of
both the polar and nonpolar constituents [5]. (erefore, to
gain an insight into the holistic potential of Flaxseed in IBD,
one of the aims of the current study was to assess the effect of
Flaxseed oil (nonpolar constituents) for its effectiveness
against IBDmodel of mice and, subsequently, compare these
parameters with Fs.Cr.
Knowing that antispasmodics have an important role in
IBD therapeutics as an adjunctive therapy [1], we also aimed
to explore the precise mode of antispasmodic mechanisms of
Flaxseed (both the extract and oil) using isolated gut tissues
from experimental animals. Earlier, we have reported that
both Fs.Cr and Flaxseed oil exhibited antidiarrheal activity
with possible involvement of Ca+2 channel inhibition and
nonspecific K+ channel activation, respectively [6, 7].
However, the possibility of other potential mechanisms was
there as the inhibitory effect in isolated jejunal tissues against
carbachol- (CCh, 1 μM) induced contractions was not
studied, which can help in identifying the presence of an-
ticholinergic and/or phosphodiesterase inhibitory mecha-
nisms [8, 9], both of which have potential for IBD
therapeutics [10, 11].
(e third aim of our study was to assess the antibacterial
activity of Flaxseed against the bacteria implicated in IBD as
microbes have an important role in IBD pathogenesis [12].
Amongst them, enteropathogenic E. coli (EPEC), enter-
otoxigenic E.coli (ETEC), and enteroaggregative E.coli
(EAEC) are implicated in IBD as they share virulence
properties with adherent invasive E.coli (AIEC) [13], a strain
isolated from biopsies of ileal Crohn’s disease (CD) patients.
Flaxseed has not been studied for its activity against these
pathogens. Hence, in the current study, efficacy and potency
of Fs.Cr and Flaxseed oil against EPEC, ETEC, and EAEC
were tested in vitro.
To sum up, our objective in the current study is to assess
the holistic potential of Flaxseed by examining and com-
paring both the extract and the oil for their protective effect
against acetic acid (AA)-induced colitis in mice, antispas-
modic mechanisms, and antibacterial activity, thus
encompassing the different triggers of IBD.
2. Materials and Methods
2.1. Standard Drugs. Acetic acid, acetylcholine chloride,
carbamoyl choline chloride, DPX, periodic acid, predniso-
lone, Schiff reagent, and verapamil hydrochloride were
purchased from Sigma Chemicals Co, St. Louis, MO, USA.
Nutrient agar and Luria-Bertani broth powders used for
antibacterial assays were also purchased from Sigma
Chemicals. Chemicals used for making physiological salt
solutions, including potassium chloride, calcium chloride,
glucose, magnesium chloride, magnesium sulfate, potassium
chloride, sodium bicarbonate, sodium dihydrogen phos-
phate, EGTA, and sodium chloride, were obtained from
Merck, Darmstadt, Germany. DMSO and Tween-80 used for
solubilization were purchased from Merck, Darmstadt,
Germany, and Scharlau Chemicals, Barcelona, Spain,
respectively. All chemicals used were of the available ana-
lytical grade. Cenogenics single strip kit was used for the
occult blood test. cAMP enzyme immunoassay kit for
multiple species was purchased from Arbor Assays, Ann
Arbor, MI, USA. (e reference drugs gentamycin was
purchased from Sigma Chemicals Co, St. Louis, MO, USA.
Nutrient agar and Luria-Bertani broth powders used for
antimicrobial assays were purchased from Sigma Chemicals
and were of the available analytical grade.
2.2. Preparation of Plant Material (Flaxseed Extract and Oil).
Linum usitatissimum. L (Flaxseed) was bought from an
authentic herb supplier in the local market of Karachi,
Pakistan. (e plant name and physical characteristics
matched the description when checked with http://www.
theplantlist.org. It appeared as deep brown flat and oval seed
with a pointed tip and measured about 4mm. A sample of
Flaxseed was deposited in the herbarium of the Department
of Biological and Biomedical Sciences of the Aga Khan
University, with a voucher number LU-SE-0812-106. (e
seeds were made free of dirt and other adulterants and were
grounded finely into powder by an electrical chopper.
(e aqueous-methanolic crude extract of Flaxseed
(Fs.Cr) was prepared from approximately 1 kg ground
Flaxseed by the process of cold maceration using aqueous
methanol (30 : 70 v/v) as a solvent for extraction. [7]. For oil
extraction, previously defined methods were used [14].
Briefly, approximately 1 kg of ground Flaxseed was soaked in
petroleum ether and kept on a water bath at 45°C for 7 days
with occasional shaking. Petroleum ether was evaporated
using Rota vapor, and the oil was filtered to clarity. Re-
spective yields of the Fs.Cr and the oil were 8 and 27% w/w
with reference to dried seeds. Both the extract and the oil
were plated on nutrient agar and incubated at 37°C for
24 hrs. (ere was no evident growth on the plate.
2.3. Animals. (e study protocol (005-Ani-BBS-13) was
approved by ECACU (Ethics Committee for Animal Care
and Use) of the Aga Khan University, which is in accordance
with the international guidelines for laboratory animal use
and care [15]. Rabbits (1–1.5 kg) of either sex and of the local
breed were used for the ex vivo study, whereas Sprague
Dawley rats (150–200 g) were used for the in vivo study.
Female BALB/c mice, 6–8 weeks old (22–30 g), were used for
the colitis study and kept in the animal house of the Aga
Khan University (Karachi), in rectangular cages
(47× 34×18 cm3) with sawdust (changed every 48 hrs). All
animals were given a standard diet and maintained under
standard conditions (temperature 22–25°C, 70–75% hu-
midity, and 12 hr light and dark cycle). Animals also had free
access to water and food ad libitum, throughout the study,
except in case of induction of colitis, where animals’ food
was withdrawn before 18 hrs and rabbits were kept on
fasting for 24 hrs before sacrificing them for ex vivo study.
Mice used for colitis study were sacrificed by cervical
dislocation 24 hrs after induction of colitis, whereas rabbits
starved for 24 hrs were anaesthetized with thiopental sodium
(200mg/kg, i.p.) and sacrificed by cervical dislocation.
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Bacterial strains used in this study included enteropatho-
genic E. coli (2348/69, EPEC), enterotoxigenic E. coli
(H10407, ETEC), and enteroaggregative E. coli. (042,
EAEC), grown aerobically at 37°C in Luria-Bertani broth
(LB) for 16 hrs.
2.4.Working Stocks. For the in vivo and ex vivo experiments,
the extract and the oil were solubilized in 10% DMSO-5%
Tween-80, and subsequent dilutions were made in distilled
water on the day of the experiment.
For determining the effect against enteric pathogens, the
Fs.Cr stock was prepared as 1000mg/ml in 50% methanol
and then centrifuged at 14,000 g for 60min.(e supernatant
was microfiltered, and subsequently a working stock was
prepared into 1mg/ml. From this working stock, Fs.Cr 10
and 20 μl were picked for the antimicrobial assay (assay
volume� 200 μl) to get the total concentration to be 50 μg/ml
and 100 μg/ml, respectively.
For positive control groups (100% kill), 10 μl of microbes
was suspended with 100 μg/ml of vancomycin (for Gram-
negative), whereas, for negative control, 10 μl of inoculum
was suspended with the corresponding volume of the vehicle
solvent (MeOH). 12.5%methanol, corresponding to the final
concentration of MeOH in Fs.Cr working solutions, was
used as vehicle control. At this concentration, there was no
effect on bacteria kill.
Flaxseed Oil was already in the liquid form and could be
easily drawn in minutest quantities; hence, no dilution was
required. 1ml (1000 μl) of oil corresponding to 1mg
(1000 μg) was centrifuged at 14000 g for 60min and sub-
sequently microfiltered. From this, 1.8 μl and 2.8 μl were
picked for assay (assay volume� 200 μl) that corresponded
to 9 μg/ml and 14 μg/ml, respectively (1.8 μg in 200 μl; for
1000 μl or 1ml, 1.8/200∗1000� 9 μg/ml).
2.5. Phytochemical Analysis. (e aqueous-methanolic crude
(30 : 70) extract of Flaxseed (Fs.Cr) was qualitatively ana-
lyzed according to standard methods for the presence or
absence of alkaloids, anthraquinones, coumarins, flavo-
noids, saponins, sterols, tannins, and terpenes [16].
2.6. Experimental Protocol. (e study design was similar to
our previously reported study [4] with a sham control group,
diseased control (untreated), positive control (predniso-
lone), and treatment groups. (ere were 12 animals in each
group. (ree treatment groups were administered 150,
300, and 500mg/kg Fs.Cr, and another three groups were
given similar doses of Flaxseed oil intraperitoneally (i.p.) for
5 days prior to the induction of colitis. On the 6th day, all
groups except the sham control group were induced with
colitis under anaesthesia. All the groups continued to receive
the respective treatments till the last day when mice were to
be sacrificed.
Acetic acid- (AA-) induced colitis model by intrarectal
(IR) administration was adopted to decipher the effect of
Fs.Cr and oil, as reported previously [4, 17]. Briefly, BALB/c
mice fasted for 18 hrs with access to water ad libitum were
anaesthetized and administered 0.1ml of 6% IR acetic acid
(v/v, in 0.9% saline) through feeding needle, held vertically
for 45 sec and then flushed with 0.1ml of saline. Mice were
sacrificed 24 hrs after the induction of colitis.
2.7. Evaluation of AA-Induced Colitis
2.7.1. Mortality Rate and DAI. (e numbers of mice dying
in the respective groups were compared to the total animals
present in the same group before start of the experiment, and
mortality rate was calculated as follows:
mortality Rate �
mice died in a group
total number of mice in that group
x 100.
(1)
Disease activity index (DAI) was assessed after 24 hrs,
which was the average of loss in body weight, effect on stool
consistency, and type of rectal bleed [18]. (e semiquanti-
tative scoring details are elaborated in Table 1.
2.7.2. Histological Assessment. After assessing DAI, mice
were sacrificed by cervical dislocation, and the colon tissues,
5 cm proximal to anus, were excised and stored in neutral
buffered formalin for 24 hrs. Histological processing of colon
tissues was done to assess colonic damage using hematoxylin
and eosin (H and E) staining, and mucus content was
assessed by periodic acid-Schiff-alcian blue (PAS-AB)
staining. For quantifying themicroscopic damage of H and E
and PAS-AB, stained sections of the colon were scored in a
single blinded fashion by a histopathologist using Neurath
et al. [19] and Vilaseca score [20], whereas goblet cells were
assessed on the basis of level of the mucin staining according
to Dorofeyev et al. [21], the details of which are presented in
Supplementary Table 1.
2.8.AntispasmodicMechanisms. Fs.Cr and Flaxseed oil were
tested for their antispasmodic mechanisms using isolated
rabbit jejunum preparations in a tissue bath assembly set-up,
for their inhibitory effect against CCh- (1 μM) induced
contractions, and for their previously reported effect on
spontaneous and high K+- [7] and low K+-induced con-
tractions [6].
2.8.1. PDE Inhibitory Activity. To assess PDE inhibitory
effect of test materials, isoprenaline-induced inhibitory
CRCs were constructed against CCh- (1 µM) induced sus-
tained contractions in isolated rabbit jejunum in the absence
and presence of the Fs.Cr and Flaxseed oil, as described
previously [22]. Since the PDEI activity of Fs.Cr was stronger
as compared to oil, Fs.Cr was further studied for its in-
hibitory effect against the subtype of PDE enzyme along with
cAMP levels in Fs.Cr tested tissues. For this purpose, a
relationship between inhibitory effects of different PDE
enzyme inhibitors was examined in the presence and ab-
sence of Fs.Cr [23, 24]. Briefly, isolated rabbit jejunal tissues
were contracted by CCh (1 µM). Once these contractions
were sustained, concentration-dependent inhibitory
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responses were constructed by cumulative dosing of PDE
enzyme subtypes 3, 4, and 5 inhibitors: cilostazol, rolipram,
and zaprinast, respectively [25]. (is was followed by
restabilization of the jejunal tissues, and then the same types
of concentration-dependent inhibitory responses of each of
the PDE subtypes 3, 4, and 5 inhibitors were constructed in
the presence of 0.03mg/ml of Fs.Cr, or one of the other types
of PDE inhibitors: cilostazol (100 μM), rolipram (3 μM), and
zaprinast (100 μM) (administered before inducing CCh-
induced contractions).(e results were interpreted based on
the potentiation of PDE inhibitor’s concentration-depen-
dent inhibitory responses with or without pretreatment of
Fs.Cr.
To confirm the PDE inhibitory effect of Fs.Cr, cAMP
content of the jejunum was measured by enzyme immu-
noassay [26] using cAMP enzyme immunoassay kit for
multiple species (Arbor Assays DetectX, Direct cAMP En-
zyme Immunoassay kit, Ann Arbor, MI, USA). For this
purpose, CCh-induced contraction of the jejunum was
inhibited with Fs.Cr in respective different doses. (en the
jejunal tissues were snap-frozen in liquid nitrogen; subse-
quently homogenized with 1ml of sample diluent for every
100mg of tissue, on ice; kept like this for 10min; and then
centrifuged at ≥6000 g at 4°C for 15min. (e supernatant
was collected and either analyzed immediately or stored
frozen at −80°C. Similar steps were repeated for tissues
treated with different doses of papaverine, which served as a
positive control, and tissues without administration of any
drug and only contracted with CCh, which served as a
negative control. (e cAMP content was expressed as pi-
comole per ml.
2.8.2. Anticholinergic Activity. In order to confirm the
involvement of anticholinergic mechanisms, first control
concentration-response curves (CRCs) of Ach were
constructed in guinea pig ileum up to the maximal effect,
and then these CRCs were reconstructed in the presence
of an increasing concentration of the plant material
(Fs.Cr and oil). (e rightward parallel shift in the CRCs
of Ach indicated the competitive antagonism [27], while
nonparallel displacement with suppression of the max-
imal response confirmed the nonspecific antagonism.
[28].
2.9. Antibacterial Assay. EPEC, ETEC, and EAEC were
assessed using the quantitative antibacterial assays as
previously reported [29]. At first, optical density (OD) of
bacteria was adjusted through Luria Broth (LB) to 0.22
corresponding to approximately 106 colony forming units
(c.f.u.), followed by making a serial dilution of bacteria at
10−1–10−6 and plating them; this became the inoculum
control. Simultaneously, in other sets of tubes, 10 µl of
respective bacterial inoculum was suspended with dif-
ferent doses of Flaxseed oil (9 μg/ml and 14 μg/ml) and
Fs.Cr (50 and 100 µg/ml); the total assay volume was
200 µl, and LB was used as an assay buffer. For negative
control, 10 µl of original inoculum (OI) was suspended
with corresponding volumes of LB instead of Flaxseed oil/
Fs.Cr. Additional negative control of the corresponding
concentration of methanol (MeOH) was used for Fs.Cr, as
it was solubilized in MeOH. For positive control groups
(100% kill), 10 µl of inoculum was suspended with 100 µg/
ml gentamycin. (e assay tubes were then incubated in
CO2 incubator for 2 hrs on shaking. After incubation,
microbial cultures were 10-fold serially diluted in LB
(10−1–10−6), plated on nutrient agar plates, and incubated
further at 37°C overnight, and microbial c.f.u. were
enumerated.
(e effect of test material was compared to the originally
incubated number of bacteria in terms of reduction in c.f.u.
in respective treatment groups. (e effect was considered as
bactericidal if the concentration of bacteria in the treated
groups was less than OI.(e percent bactericidal effects were
determined as follows:
100 −
c.f .u. in extract
original inoculum
( )∗100[ ]. (2)
(e conclusions were drawn based on colony count as
follows:
(1) If the microbial c.f.u. was less than the c.f.u. in OI, it
was considered as a bactericidal effect
(2) If the microbial c.f.u. was similar to OI or greater
than OI, it was inferred that test material has no
effect
2.10. Statistical Analysis. (e data expressed are mean-
s ± standard error of the mean (SEM; n: number of ex-
periments). One-way ANOVA was applied to differentiate
the results in cyclic AMP (cAMP) assay. A probability of
p< 0.05 was considered significant. (e concentration-
response curves (CRCs) were analyzed by nonlinear re-
gression using the GraphPad program (GraphPad, San
Diego, CA, USA). (e antibacterial analysis was deter-
mined by unpaired t-test (two-tailed) or one-way ANOVA
followed by Tukey’s posttest. All other graphing, calcula-
tions, and statistical analyses were also carried out using
GraphPad software (GraphPad, San Diego, California,
USA).
Table 1: Disease activity index (DAI) scoring criteria.
Parameter Scoring criteria
Weight loss 1–5%, 6–10%, 11–20%,> 21%� 0, 1, 2, 3
Stool Normal, soft but still formed, very soft, diarrhoea� 0, 1, 2, 3
Bleed/occult Normal, hemoccult positive, blood traces in stool visible, gross bleeding = 0, 1, 2, 3
DAI (Weight loss + stool consistency + rectal bleeding)/3
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3. Results
3.1. Phytochemistry. Preliminary phytochemical analysis of
the aqueous-methanolic crude extract of Flaxseed (Fs.Cr)
revealed the presence of tannins, flavonoids, triterpenes,
alkaloids, and coumarins, whereas saponins were weak and
anthraquinones were not detected.
3.2. Evaluation of the Effect on the Ulcerative Colitis Model.
(e effects of Flaxseed oil and Fs.Cr at the doses of 150, 300,
and 500mg/kg were tested against AA-induced colitis.
3.2.1. Mortality Rate and DAI. (emortality rate of 6% AA-
induced colitis mice (untreated) was 58%, whereas pre-
treatment with Flaxseed oil and extract reduced the mor-
tality rate significantly (p< 0.01 vs p< 0.001 at 300 and
500mg/kg doses, respectively). (e optimal effect of Fs.Cr
was at 300mg/kg dose, whereas Flaxseed oil’s optimal effect
was evident at 500mg/kg dose. (e effect of oil at 500mg/kg
dose was superior to that of the extract (8.33± 5% vs
33± 6%).
Overall, both the extract and oil improved the DAI
significantly as compared to diseased control. Fs.Cr im-
provement in DAI started at 150mg/kg, whereas Flaxseed oil
improved DAI at 300mg/kg dose. Both Flaxseed oil and
extract were effective at 300mg/kg doses, with Fs.Cr being
more effective at this dose, whereas Flaxseed oil exhibited
maximum improvement in DAI at 500mg/kg dose (Table 2).
3.2.2. Microscopic Damage. Both the extract and oil were
equally efficacious in improving the microscopic damage
parameters when compared to diseased control. However,
the type of protective effect was different for both Fs.Cr and
Flaxseed oil.
Both Flaxseed oil and Fs.Cr were equally efficacious in
reducing neutrophil infiltration (Neurath score) except that
Fs.Cr was more potent than Flaxseed oil. (e colonic
damage scores showed significant dose-dependent reduction
by Fs.Cr, with maximum reduction by 55.18% at 300mg/kg
dose, and the oil also showed similar efficacy (55.89% re-
duction in Neurath score) but at 500mg/kg dose. When the
microscopic damage was quantified using Vilaseca score
[20], which is the sum of the size of ulceration, inflam-
mation, and depth of lesion, Flaxseed oil was more effica-
cious in reducing ulcers (max effect: 77.5% at 500mg/kg
dose) as compared to Fs.Cr (max effect: 56% at 300mg/kg
dose). Fs.Cr was slightly more efficacious than Flaxseed oil in
reducing the inflammation (50% vs 35.46% respectively) and
depth of lesion (55% vs 42.31% respectively).
(e effects of Flaxseed extract and oil were compared for
their effectiveness in increasing the mucin score, as com-
pared to diseased control. Fs.Cr was both potent and effi-
cacious (92% mucin increase) in promoting mucin
production as compared to oil (maximum mucin produc-
tion: 42.28%). (e percentage difference is elaborated in
Table 3, whereas the scores are illustrated in Supplementary
Table 2.
3.3.AntispasmodicMechanisms. Both Fs.Cr and Flaxseed oil
were studied for their effect against CCh-, high K+-, and low
K+-induced contractions in a spontaneously contracting
rabbit jejunum, to assess and confirm their possible anti-
spasmodic mechanisms.
When compared for inhibitory effect against different
spasmogens, Fs.Cr showed selectivity for CCh-induced
contractions (Figure 1(a)), exhibiting inhibitory effect at
lower doses, similar to that of papaverine (Figures 1(c) and
1(d)), whereas verapamil showed higher potency against
high K+ when compared with carbachol (Figure 1(d)).
Similarly, Flaxseed oil exhibited inhibitory effect against
CCh- (1 μM) induced contractions at a higher concentration
of 5mg/ml (Figure 1(b)); hence, Fs.Cr was more potent
against CCh- (1 μM) induced contractions (p< 0.01) as
compared to Flaxseed oil. In contrast, Flaxseed oil was found
selective at the activation of K+ channels, which was absent
in Fs.Cr at the tested doses, whereas its effect against high K+
was negligible as previously reported [6] (Figure 1(b)).
Any material that will inhibit CCh-induced contraction
is either PDEI, anticholinergic, or both [26]. Hence, Fs.Cr
was further explored for its anticholinergic and PDEI
mechanisms.
3.3.1. PDEI Activity of Fs.Cr and Flaxseed Oil. To test for the
presence or absence of PDEI-like effect, inhibitory CRCs of
isoprenaline were constructed against CCh-induced sus-
tained contractions (Figures 2(a)–2(d)) in the presence and
absence of Fs.Cr (Figure 2(a)) and Flaxseed oil (Figure 2(b))
in rabbit jejunal tissues. Pretreatment of the jejunal tissues
with increasing concentrations of Fs.Cr (0.01 and 0.03mg/
ml) and Flaxseed oil (1mg/ml and 3mg/ml) shifted the
isoprenaline-induced inhibitory CRCs against CCh (1 μM)
to the left, indicating PDEI, similar to papaverine at 1 and
3 μM (Figure 2(c)), whereas there was no shift in the case of
verapamil (0.03 and 0.1 μM) (Figure 2(d)). Due to the strong
PDEI effect of Fs.Cr, it was further explored for in-depth
mechanisms for its subtype and the associated increase in
cAMP levels.
Since PDE inhibitory effect was the predominant
mechanism for the antispasmodic activity of Fs.Cr, it was
further studied for the possible subtype of PDE involved.
PDEI are expected to inhibit CCh-induced sustained con-
tractions. Hence, at first, the effect of different PDE in-
hibitors’ subtypes against CCh-induced contraction, with
and without pretreatment with Fs.Cr, was recorded
(Figures 3(a)–3(c)).
Cilostazol, a selective inhibitor of PDE-3, showed a
concentration-dependent inhibitory response against CCh-
induced contraction as evident in Figures 3(a). Pretreatment
with Fs.Cr potentiated the inhibitory effect of cilostazol
(p< 0.001), as evident by a leftward shift in the curve along
with a significant reduction in EC50 values (additive effect)
(Table 4). A similar pattern was evident when effect of
cilostazol was measured with preincubation of rolipram
(PDE-4 subtype inhibitor) and zaprinast (PDE-5 subtype
inhibitor) indicating that Fs.Cr may have inhibited a PDE
subtype other than cilostazol. A similar leftward shift was
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evident when inhibitory CRC was constructed against
zaprinast, in presence of Fs.Cr and other standard PDE
inhibitors.
Rolipram, a selective inhibitor of PDE-4, inhibited the
contraction induced by CCh in a concentration-dependent
manner. Interestingly, the inhibitory response of rolipram
was not potentiated by pretreatment with Fs.Cr, whereas it
was significantly potentiated by pretreatment with cilostazol
(p< 0.001) and also zaprinast (p< 0.001) as evident in
Figures 3(b). Hence, it is concluded that Fs.Cr might be
inhibiting PDE-4 subtype similar to rolipram, a standard
PDE-4 inhibitor.
Since cAMP levels are increased when PDE enzyme is
inhibited in the tissues [30], we also estimated the cAMP
levels in the control CCh-treated tissues and compared
them with Fs.Cr- and papaverine-pretreated jejunal
tissues. Untreated tissues showed 16.89 ± 1.42 pmol of
cAMP/ml of tissue homogenate. Compared to this, Fs.Cr
after treatment with 1, 3, and 5mg/ml of Fs.Cr against
CCh-induced contraction showed cAMP levels up to
29.11 ± 1.62 (p< 0.05), 65.99 ± 1 (p< 0.001), and
78.73 ± 1.17 (p< 0.001) pmol/ml, respectively, as evident
in Figure 4(a). (e papaverine control showed similar
pattern of the rise in the cAMP levels with control CCh-
treated tissues showing cAMP levels of
21.01 ± 1.75 pmol/ml, whereas treatment with 1 μM and
3 μM of papaverine in CCh-contracted tissues increased
the cAMP levels to 58.7 ± 4.2 pmol/ml (p< 0.05) and
91.89 ± 3.4 (p< 0.001) pmol/ml, respectively, as evident
in Figure 4(b).
Table 3: Comparison of histopathological scoring for Flaxseed oil and extract.
Oil % reduction from control Extract % reduction from control Oil vs. extract
Vilaseca score
Ulceration
Untreated
150mg/kg 3.13% 24% ∗∗∗
300mg/kg 25% 56%∗ ∗∗∗
500mg/kg 77.5%∗∗ 33.14% ∗∗∗
Inflammation
150mg/kg 2.27% 8.5% ∗∗∗
300mg/kg 13.64% 50%∗∗∗ ∗∗∗
500mg/kg 35.46%∗∗ 30% NS
Depth of lesion1
150mg/kg 7.69% 23.07%∗
300mg/kg 23.08%∗∗ 55%∗∗∗ ∗∗∗
500mg/kg 42.31%∗∗∗ 38.47%∗∗∗ NS
Neurath score
150mg/kg 8.82% 33.04% ∗∗
300mg/kg 26.47%∗∗ 55.18%∗ ∗∗∗
500mg/kg 55.89%∗∗∗ 51.15%∗∗ NS
Mucin score (%)
150mg/kg 2.85% 25% ∗∗∗
300mg/kg 35.71%∗ 75%∗∗∗ ∗∗∗
500mg/kg 42.28%∗∗ 91.66%∗∗∗ ∗∗∗
Neurath score [19]: score 0� no leukocyte infiltration; score 1� low level of leukocyte infiltration; score 2�moderate level of leukocyte infiltration; score
3�moderate level of leukocyte infiltration, high vascular density, and thickening of colon wall; score 4� transmural leukocyte infiltration, loss of goblet cells,
high vascular density, and thickening of the colon wall. Vilaseca Score [20]: total score� 9 ulceration: 1 [no ulcer, epithelialization; small ulcers< 3mm; large
ulcers≥ 3mm� score 0, 1, 2, respectively]; inflammation: 3 [none, mild, moderate, severe; 0, 1, 2, 3]; depth of lesion: 3 [none, mucosa, muscularis propria,
serosa; 0, 1, 2, 3]; mucin score [21]: score 4 [<1% of stained cells; 1–30% of stained cells (low level of staining); 30–80% of stained cells (medium level of
staining); up to 80% of stained cells� score 0, 1, 2, 3]. One-way ANOVA followed by Tukey’s posttest was used for analysis. Values expressed are means± SEM
(n� 6). ∗p< 0.05, ∗∗ � p< 0.01; ∗∗∗ � p< 0.001 vs AA. #Diseased control group. Two-way ANOVA followed by Bonferroni’s posttest was used for comparing
the effect of corresponding doses of Flaxseed oil and extract. All the drugs were administered i.p. Colitis was induced by IR administration of 0.1ml 6% acetic
acid during anaesthesia. Tissues were embedded in formalin for another 24 hrs, then processed, and stained with H and E and PAS-AB staining. i.p.:
intraperitoneally; IR: intrarectal; H and E: hematoxylin and eosin; PAS-AB: periodic acid-Schiff-Alcian blue.
Table 2: Comparison of mortality rate and DAI of acetic acid-induced colitis in mice.
Mortality rate (%) DAI (%)
Oil Extract Oil Extract
Untreated 58.33± 4.23# 50± 5.01% 2.17± 0.06 2.11± 0.03#
150mg/kg 55± 12% 33.33± 5%∗ 2.1± 0.08 1.17± 0.01∗
300mg/kg 33.33± 6%∗∗ 25± 8%∗∗ 1.80± 0.02∗∗ 0.71± 0.21∗∗
500mg/kg 8.33± 5%∗∗∗ 33± 6%∗∗∗ 0.93± 0.01∗∗∗ 0.97± 0.23∗∗
Values given are means± SEM of 3 experiments (n� 12). One-way ANOVAwas used for statistical analysis followed by Tukey’s posttest. ∗p< 0.05, ∗∗p< 0.01;∗∗∗p< 0.001 compared with the untreated group (#); all the drugs were administered intraperitoneally for 7 days. Colitis was induced on the 6th day with
intrarectal administration of 0.1ml 6% acetic acid. Mice were assessed 24 hrs after induction of colitis. DAI [18]� (weight loss + stool consistency + rectal
bleeding)/3; mortality rate� (mice died in a group/total number of mice in that group)× 100. DAI: disease activity index.
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3.3.2. Anticholinergic Activity of Fs.Cr and Flaxseed Oil.
Besides PDEI, CCh-induced contraction is also inhibited by
anticholinergics; therefore, Flaxseed extract and oil were
further tested in rabbit jejunal tissues to see if anticholinergic
activity exists. Pretreatment of Fs.Cr (0.1 and 0.3mg/ml)
shifted Ach-induced bolus CRCs to the right in parallel
manner without suppression of the maximal response, in a
concentration-dependent manner as shown in Figure 5(a).
With further increase in the dose of extract at 1mg/ml, the
rightward shift in Ach CRCs was nonparallel with sup-
pression in maximal response. Dicyclomine, which is known
to exhibit a cholinergic antagonist effect at a lower dose and
CCB at a higher dose, was used as a standard and showed a
similar rightward parallel shift of Ach CRCs at 0.03 μM
(p< 0.05) and a rightward nonparallel shift due to sup-
pression of the maximal response at 0.1 μM, as shown in
Figure 5(c).
Flaxseed oil shifted Ach-induced bolus CRCs to the right
in parallel manner without suppression of the maximal
response, at higher doses of 1, 3, and 5mg/ml in a con-
centration-dependent manner as shown in Figure 5(b),
similar to atropine, as shown in Figure 5(d). (is further
indicates that Fs.Cr was more potent anticholinergic than
Flaxseed oil.
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Figure 1: Inhibitory effect of aqueous-methanolic crude extract of Flaxseed (Fs.Cr) (a), Flaxseed oil (b), papaverine (c), and verapamil (d)
against CCh-, high K+- (80mM), and low K+- (25mM) induced contractions in isolated rabbit jejunal preparations.
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3.4. Antibacterial Activity. Both Flaxseed extract (Fs.Cr)
and oil were tested in vitro for their effect against EPEC,
ETEC, and EAEC. Flaxseed oil was more potent and ef-
ficacious against all the tested bacteria, as compared to
Fs.Cr. (e bactericidal effect of Flaxseed oil increased
dose-dependently at 9 and 14 μg/ml (Figures 6(a)–6(c)),
whereas the effect of Fs.Cr was only evident against EPEC
at 100 μg/ml, and no effect was observed against ETEC and
EAEC (Figures 6(d)–6(f )). (e colony counts (c.f.u.) are
elaborated in Supplementary Table 3. Hence, the minimal
effective dose for antibacterial activity against these
bacteria is almost 100 μg/ml for Fs.Cr and 9 μg/ml for
Flaxseed oil.
Since Fs.Cr did not exhibit bactericidal activity against
ETEC and EAEC, a possibility of bacteriostatic mechanism
was tested by increasing the incubation time from 2 to 16 hrs
(to provide time for bacteria to grow). Doses of 5 and
12.5mg/ml of Fs.Cr were used for assay time of 16 hrs,
whereas doses of 0.05 and 0.1mg (50 and 100 µg/ml) of Fs.Cr
were used when assay time was 2 hrs. (e analysis is shown
in Supplementary Figures 2–4 (A-B).
4. Discussion
Inflammatory bowel disease (IBD) is a manifestation of
multiple dysregulations acting simultaneously; therefore, it
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Figure 2: Concentration-response curves (CRCs) of isoprenaline.
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Figure 3: ((a)–(c)) Effect of Fs.Cr on the relaxant responses of cilostazol (a), zaprinast (b), and rolipram (c) in rabbit jejunum precontracted
with CCh (1 μM).
Table 4: EC50 values of different PDE-subtype inhibitors with and without Fs.Cr pretreatment.
PDE inhibitor
Cilostazol (µM) Control +Fs.Cr +Rolipram +Zaprinast
EC50 156.3# 0.91∗∗∗ 0.15∗∗∗ 2.83∗∗∗
CI 76.32 to 319.9 0.35 to 2.35 0.06 to 0.39 1.48 to 5.41
Rolipram (µM) Control +Fs.Cr +Cilostazol (µM) +Zaprinast
EC50 12.41# 10.34 2.421∗∗∗ 1.61∗∗∗
CI 6.42 to 23.98 5.49 to 19.46 1.21 to 4.83 0.96 to 2.70
Zaprinast (µM) Control +Fs.Cr +Rolipram +Cilostazol
EC50 146.3# 3.59∗∗∗ 19.28∗∗∗ 0.38∗∗
CI 74.45 to 287.4 1.381 to 9.37 11.91 to 31.21 0.15 to 0.96
EC50: effective concentration to produce 50% response; CI: confidence interval; Fs.Cr: aqueous-methanolic crude extract of Flaxseed (70; 30). All con-
centrations are in µM. ∗∗∗p< 0.001; ∗∗p< 0.01; one-way ANOVA was done followed by Tukey’s posttest to compare the significance of means± SEM of
controls with other groups. #All treatment groups are compared with Control.
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Figure 4: Effect of Fs.Cr (a) and papaverine (b) on the cyclic nucleotide content of rabbit jejunum.
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Figure 5: Continued.
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needs to be catered from different ends for an effective
disease control. Multitargeted approach has gained a lot of
interest in IBD therapeutics [1]; therefore, we explored the
various pharmacological targets of Flaxseed in order to
rationalize its medicinal use in IBD.
Our preliminary studies have shown that Flaxseed ex-
tract (Fs.Cr) was effective against 6% AA-induced colitis in
mice due to its antioxidant and anti-inflammatory activities
[4]. However, this does not represent the potential of whole
Flaxseed, as the extract, so prepared, mainly constitutes
polar compounds of Flaxseed [5]. Hence, we studied dif-
ferent mechanisms of both Flaxseed extract (known to
contain polar constituents) and oil (known to contain
nonpolar constituents) and then compared their effects on
various parameters implicated in IBD.
(e first step was to identify the effectiveness of Flaxseed
oil against IBD and compare it with Flaxseed extract (Fs.Cr).
It was evident with parameters such as mortality rate, disease
activity index (DAI), and microscopic scoring that Flaxseed
oil was as effective in ameliorating the severity of IBD in
mice model as Fs.Cr; however, there were some differences.
One of the differences was that Fs.Cr was more potent than
Flaxseed oil in producing these effects. Flaxseed oil was more
efficacious in reducing ulcer size as compared to Fs.Cr
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Figure 5: Concentration-response curves of Ach in the absence and presence of the increasing concentrations of (a) Fs.Cr, FS oil (b),
dicyclomine (c), atropine (d), and verapamil (e) in isolated rabbit jejunum preparations.
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Figure 6: Bar charts show colony counts of ∼106 EPEC (a, d); ETEC (b, e); and EAEC (c, f ) incubated with and without Flaxseed oil (a–c)
and Flaxseed extract (Fs.Cr) (d–f).
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reduction in neutrophil, and lymphocytic infiltration was
slightly better with Fs.Cr than Flaxseed oil. Fs.Cr was also
more potent and efficacious in promoting mucin production
than Flaxseed oil. Despite these advancements, the mortality
rate of Flaxseed oil was less as compared to Fs.Cr Differences
in inflammatory and mucosal protective parameters in the
extract and oil indicate that both the polar and nonpolar
fractions of Flaxseed have the potential to mediate mucosal
protective effect in the IBDmodel of mice andmay provide a
synergistic effect when given as a whole seed.(is seems true
as Flaxseed and its oil showed clinical improvement in ul-
cerative colitis patients in one of the latest reported studies
[31]. On the contrary, our current findings are in contrast to
an earlier report, where 10% Flaxseed diet aggravated the
severity of dextran sodium sulfate- (DSS-) induced colitis
model of mice [32]. One of the possibilities for this could be
that Flaxseed meal has a laxative effect [33], which is known
to aggravate colitis. Nevertheless, improvement in clinical
studies in UC patients shows that this may not be the case, or
this aspect may vary depending on the severity of the disease.
In the clinical study, patients who were not on corticoste-
roids and/or immune modulators were opted for, which
means that the recruited UC patients have limited disease
severity. More animal and clinical studies are needed to
clarify this aspect.
(e other part of our study aimed to identify the
mechanisms of Flaxseed in terms of its antispasmodic effect.
Interestingly, not only did we find the antispasmodic
mechanisms, but we also got some lead for its anti-in-
flammatory effect. We found that both Fs.Cr and Flaxseed
oil caused complete inhibition of CCh-induced contraction,
compared with other spasmogens, which is indicative of
PDE inhibitory activity and/or anticholinergic activity
[26, 34]. Upon further experimentation, it was evident that
Fs.Cr not only exhibited a stronger PDEI, but also increased
the tissue cAMP levels. Hence, we further aimed to identify
which subtype of PDEI receptor was inhibited. It was found
that Fs.Cr mediated the similar inhibitory pathway for PDE
enzyme as rolipram, a standard PDE4 inhibitor. (is was
identified because Fs.Cr and rolipram given simultaneously
could not produce synergistic inhibitory effect against CCh-
induced contraction, whereas other PDEI, when coad-
ministered with Fs.Cr, potentiated the effect, indicating that
perhaps rolipram and Fs.Cr worked through the same
subtype of PDE enzyme. (is interpretation is further
supported by previous studies where the effect of one of the
subtypes of PDE inhibitors has been potentiated against
CCh-induced contraction when pretreated with the other
subtypes of PDE inhibitor [23, 24, 30]. (is finding has a
very important implication because blocking PDE-4 enzyme
has been proposed as one of the novel approaches to target
IBD. PDE-4 enzymes are present on inflammatory cells, and
their inhibition prevents mucosal damage and subsequent
inflammatory cell infiltration by increasing cAMP [35]. Our
findings are also relatable because subsequently we were able
to show the increased level of cAMP in the Fs.Cr-treated
tissues, which is the end result of PDE-4 subtype inhibition.
Interestingly, in the HPLC fingerprints of Fs.Cr (unpub-
lished), one of the peaks matched quercetin, a flavonoid that
has lately been identified as a potential PDE-4 inhibitor [36],
and has been shown to ameliorate the severity of acetic acid
colitis in rats [37].
Fs.Cr was the most potent against CCh-induced con-
traction, resembling papaverine. It was however different in
that it showed some selectivity against high K+, like
dicyclomine, whereas papaverine showed similar inhibi-
tion against both spontaneous and high K+-induced con-
tractions. (is raised the possibility of an additional
anticholinergic along with Ca+2 antagonist-like activity,
similar to dicyclomine component at a higher dose. In-
terestingly, when tested for its anticholinergic activity,
Fs.Cr, at 0.3 and 1mg/ml concentrations, caused the
rightward shift of the CRCs of Ach without suppression of
the maximum response, a classic pattern of a competitive
antagonist [27] such as dicyclomine. Expectedly, at the
higher concentration of 3mg/ml, Fs.Cr further shifted the
CRCs of Ach to the right but suppressed the maximal
response, possibly due to the Ca+ channel antagonist-like
mechanism, which has also been reported earlier [7].
Hence, Fs.Cr has been proved to exhibit multiple anti-
spasmodic mechanisms ranging from PDEI-like effect at a
lower concentration, followed by anticholinergic at a rel-
atively higher concentration and Ca+ antagonist-like effect
at a further higher concentration. Contrary to the extract,
Flaxseed oil mediated antispasmodic effect predominately
through K+ channel opener (KCO) activity [6]. Both PDEI
and anticholinergic activity were evident in oil at a rela-
tively higher concentration, whereas CCB activity could
not be observed. However, the possibility of some addi-
tional mechanisms cannot be ruled out.
With current findings, Flaxseed as a whole mediates
antispasmodic action through multiple mechanisms in-
cluding PDEI (subtype PDE-4), anticholinergic, KCO, and
Ca+2 antagonist-like activities. All of these mechanisms are
known to have a protective role in IBD [10, 11, 13] and thus
provide an additional pharmacological basis for the effec-
tiveness of Flaxseed’s protective effect in IBD.
Besides therapeutic use of antispasmodics in IBD, an-
tibacterials also are used as an adjunct because reducing the
aggressive microbial load has shown improvement in clinical
outcomes in patients with IBD [38, 39]. (erefore, in the
current study, we targeted a few of the E. coli strains im-
plicated in IBD. Flaxseed oil showed a bactericidal activity
against all the three strains tested, but Fs.Cr was bactericidal
against EPEC. (is difference in efficacy and potency in-
dicates that Flaxseed oil may have a different antibacterial
mechanism or additional chemical constituent(s) with an-
tibacterial activity.
(e bactericidal effect of both Fs.Cr and Flaxseed oil
against EPEC is a very important finding because EPEC’s
invasive level is more or less similar to AIEC strain (LF82)
[13]. Moreover, EPEC has also been shown to sustain
iodoacetamide-induced UC-like colitis in rats [40]. Hence,
Flaxseed may reduce the invasive ability of E.coli in IBD
patients and possibly its consequent manifestation that
includes upregulation of NF-kβ [41], modulation of IL-1β,
IL-6, TNF-α, COX-2, and apoptosis, hence reducing in-
flammatory cascades. (is effect coupled with the earlier
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reported antibacterial activity of Fs.Cr against Salmonella
typhi [7], which is implicated in UC [39], and other Gram-
positive and Gram-negative organisms [7, 42] provides
another pharmacological basis for medicinal use of Flaxseed
in IBD. (is effectiveness of Fs.Cr could be correlated with
the resemblance of HPLC peaks of Fs.Cr with two synthetic
compounds that we have identified in one of our unpub-
lished reports. (ose compounds are ofloxacin and met-
ronidazole, both of which have broad-spectrum coverage
against aerobic and anaerobic pathogens [43]. However, the
presence of some novel compounds is speculated based on
100% kill of VRE, which is resistant to conventional anti-
biotics. On the other hand, Flaxseed oil used in the current
study exhibited a peak at later retention times (supple-
mentary Figure 1), indicating the presence of polar con-
stituents when analyzed through HPLC. (is peak may
correspond to alpha linolenic acid (ALA), as identified in
previous reports [44], that has also exhibited effectiveness in
the colitis model of mice [45]. Future studies will be directed
toward the confirmation of these active constituents and
their contribution to ameliorating effects in IBD.
(is study is the first report on the effect of Flaxseed on
bacteria implicated in IBD. Earlier, antibacterial effect of
Flaxseed oil has been shown against E.coli [42], which is a
nonpathogenic strain and hence cannot be compared. (e
current study shows that Flaxseed has bactericidal effect
against pathogens implicated in IBD, which may contribute
to managing immune dysregulation from a different end
than cytokine modulation.
5. Conclusion
Based on the current findings, we understand that both
Flaxseed oil and extract are effective against IBD model of
mice, with possibly different mucosal protective mecha-
nisms. Both the extract and the oil exhibit antispasmodic
activity with partly similar mechanisms. Fs.Cr has pre-
dominant PDE inhibitor-like effect and weaker Ca++ an-
tagonist effect, whereas Flaxseed oil has predominant KCO-
like effect and weak PDEI effect. Both the extract and the oil
are effective against microbes implicated in IBD, with a
stronger antibacterial activity in Flaxseed oil. (is, coupled
with previously reported cytokine modulatory and antiox-
idant effects of Fs.Cr, indicates that the whole seed must
encompass the potential of both the extract and the oil and
therefore shall give an augmented response in IBD. Hence,
Flaxseed may become a choice of remedy that helps to cater
the basic pathophysiological tenets of IBD, which involve
immune dysregulation and barrier defects as well as mi-
crobial dysregulation.
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